Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients
Benjamin Hebraud,Xavier Leleu,Valérie Lauwers-Cances,Murielle Roussel,Denis Caillot,Gerald Marit,Lionel Karlin,C. Hulin,C Gentil,François Guilhot,Laurent Garderet,T. Lamy,Sabine Brechignac,Brigitte Pegourie,Jérôme Jaubert,Mamoun Dib,Stoppa Am,Catherine Sebban,Cecile Fohrer,Jean Fontan,Christophe Fruchart,Margaret Macro,Frédérique Orsini-Piocelle,Gérard Lepeu,Claudine Sohn,Jill Corre,Thierry Facon,Philippe Moreau,M. Attal,Hervé Avet-Loiseau +29 more
Reads0
Chats0
TLDR
The data show that 1p22 and 1p32 deletions are major negative prognostic factors for PFS and OS for patients with MM, and it is suggested that 1 p32 deletion should be tested for all patients at diagnosis.Abstract:
Deletions of the 1p region appear as a pejorative prognostic factor in multiple myeloma patients (especially 1p22 and 1p32 deletions) but there is a lack of data on the real impact of 1p abnormalities on an important and homogeneous group of patients. To address this issue we studied by fluorescence in situ hybridization (FISH) the incidence and prognostic impact of 1p22 and 1p32 deletions in 1195 patients from the IFM (Institut Francophone du Myelome) cell collection. Chromosome 1p deletions were present in 23.3% of the patients (271): 15.1% (176) for 1p22 and 7.3% (85) for 1p32 regions. In univariate analyses, 1p22 and 1p32 appeared as negative prognostic factors for progression-free survival (PFS): 1p22: 19.8 months vs 33.6 months (P<0.001) and 1p32: 14.4 months vs 33.6 months (P<0.001); and overall survival (OS): 1p22: 44.2 months vs 96.8 months (P=0.002) and 1p32: 26.7 months vs 96.8 months (P<0.001). In multivariate analyses, 1p22 and 1p32 deletions still appear as independent negative prognostic factors for PFS and OS. In conclusion, our data show that 1p22 and 1p32 deletions are major negative prognostic factors for PFS and OS for patients with MM. We thus suggest that 1p32 deletion should be tested for all patients at diagnosis.read more
Citations
More filters
Journal ArticleDOI
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
Pieter Sonneveld,Hervé Avet-Loiseau,Sagar Lonial,Saad Z. Usmani,David S. Siegel,Kenneth C. Anderson,Wee Joo Chng,Philippe Moreau,Michel Attal,Robert A. Kyle,Jo Caers,Jens Hillengass,Jesús F. San Miguel,Niels W.C.J. van de Donk,Hermann Einsele,Joan Bladé,Brian G.M. Durie,Hartmut Goldschmidt,Maria-Victoria Mateos,Antonio Palumbo,Robert Z. Orlowski +20 more
TL;DR: Based on data available today, bortezomib and carfilzomib treatment appear to improve complete response, progression-free survival, and overall survival in t(4;14) and del(17/17p), whereas lenalidomide may be associated with improved progression-based survival and progression- free survival int( 4;14), del( 17/17 p), and t(14;16), and gain(1q).
Journal ArticleDOI
IMWG consensus on risk stratification in multiple myeloma
Wee Joo Chng,Angela Dispenzieri,C. S. Chim,R Fonseca,H. Goldschmidt,Suzanne Lentzsch,Nikhil C. Munshi,Antonio Palumbo,Jesus-Fernando San Miguel,Pieter Sonneveld,Michele Cavo,Saad Z. Usmani,Brian G.M. Durie,Hervé Avet-Loiseau +13 more
TL;DR: The International Myeloma Working Group proposes well-defined and easily applicable risk categories based on current available information and suggests the use of this set of prognostic factors as gold standards in all clinical trials and form the basis of subsequent development of more complex prognostic system or better prognostic Factors.
Journal ArticleDOI
Evolutionary biology of high-risk multiple myeloma
TL;DR: This Review discusses end-stage high-risk disease states and how new information is improving the understanding of their evolutionary trajectories, how they may be diagnosed and the biological behaviour that must be addressed if they are to be treated effectively.
Journal ArticleDOI
Interpretation of cytogenetic results in multiple myeloma for clinical practice
A M Rajan,S V Rajkumar +1 more
TL;DR: A review of how multiple myeloma is classified into specific subtypes based on primary cytogenetic abnormalities is provided to provide a concise overview of how to interpret cytogenetics abnormalities based on the disease stage to aid clinical practice and patient management.
Journal ArticleDOI
Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting
Paul G. Richardson,Jesús F. San Miguel,Philippe Moreau,Roman Hájek,Meletios A. Dimopoulos,Jacob P. Laubach,Antonio Palumbo,Katarina Luptakova,Dorothy Romanus,Tomas Skacel,Shaji Kumar,Kenneth C. Anderson +11 more
TL;DR: The complexity of interpreting data across clinical studies in MM, as well as between clinical studies and routine-care analyses, is demonstrated to help clinicians consider all the necessary issues when tailoring individual patients’ treatment approaches.
References
More filters
Journal ArticleDOI
International staging system for multiple myeloma.
Philip R. Greipp,Jesús F. San Miguel,Brian G.M. Durie,John Crowley,Bart Barlogie,Joan Bladé,Mario Boccadoro,J. Anthony Child,Hervé Avet-Loiseau,Robert A. Kyle,Juan J. Lahuerta,Heinz Ludwig,Gareth J. Morgan,R. L. Powles,Kazuyuki Shimizu,Chaim Shustik,Pieter Sonneveld,Patrizia Tosi,Ingemar Turesson,Jan Westin +19 more
TL;DR: The new International Staging System (ISS) is simple, based on easy to use variables (Sbeta2M and serum albumin), and recommended for early adoption and widespread use.
Journal ArticleDOI
A note on quantifying follow-up in studies of failure time
Michael Schemper,Terry L. Smith +1 more
TL;DR: It is shown that values of median follow-up may differ substantially depending on the method used, and standard analytical methods for survival data, such as the log-rank test 121, the generalized Wilcoxon test, or the proportional hazards model 141, estimate average effects for the observed response times and test those effects for significance.
Journal ArticleDOI
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome
Hervé Avet-Loiseau,Michel Attal,Philippe Moreau,Catherine Charbonnel,Frédéric Garban,Cyrille Hulin,Serge Leyvraz,Mauricette Michallet,Ibrahim Yakoub-Agha,Laurent Garderet,Gerald Marit,Lucienne Michaux,Laurent Voillat,Marc Renaud,Bernard Grosbois,Gaelle Guillerm,Lotfi Benboubker,Mathieu Monconduit,Catherine Thieblemont,Philippe Casassus,Denis Caillot,Anne-Marie Stoppa,Jean-Jacques Sotto,Marc Wetterwald,Charles Dumontet,Jean-Gabriel Fuzibet,Isabelle Azais,Véronique Dorvaux,Marc Zandecki,Régis Bataille,Stephane Minvielle,Jean-Luc Harousseau,Thierry Facon,Claire Mathiot +33 more
TL;DR: In myeloma, the genomic aberrations t(4;14) and del(17p), together with beta2-microglobulin level, are important independent predictors of survival and have implications for the design of risk-adapted treatment strategies.
Journal ArticleDOI
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.
Rafael Fonseca,P L Bergsagel,Johannes Drach,John D. Shaughnessy,Norma C. Gutiérrez,Alexander Keith Stewart,Gareth J. Morgan,B Van Ness,Marta Chesi,Stephane Minvielle,Antonino Neri,Bart Barlogie,W. M. Kuehl,Peter Liebisch,Faith E. Davies,Selina Chen-Kiang,Brian G.M. Durie,Ruben D. Carrasco,Orhan Sezer,Tony Reiman,Linda M. Pilarski,Hervé Avet-Loiseau,Hervé Avet-Loiseau +22 more
TL;DR: In this paper, the authors proposed a framework for the classification of myeloma subtypes and provided recommendations for genetic testing, which needs to be incorporated into daily clinical practice and also as an essential component of all ongoing and future clinical trials.
SPOTLIGHT REVIEW International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
R Fonseca,P L Bergsagel,Johannes Drach,John D. Shaughnessy,Norma C. Gutiérrez,Alexander Keith Stewart,G Morgan,B Van Ness,Marta Chesi,Stephane Minvielle,Antonino Neri,Bart Barlogie,W. M. Kuehl,Peter Liebisch,Faith E. Davies,Selina Chen-Kiang,Ruben D. Carrasco,Orhan Sezer,Tony Reiman,Linda M. Pilarski,Hervé Avet-Loiseau,Samuel Oschin +21 more
TL;DR: It is proposed that genetic testing needs to be incorporated into daily clinical practice and also as an essential component of all ongoing and future clinical trials.
Related Papers (5)
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Antonio Palumbo,Hervé Avet-Loiseau,Stefania Oliva,Henk M. Lokhorst,Hartmut Goldschmidt,Laura Rosiñol,Paul G. Richardson,S. Caltagirone,Juan J. Lahuerta,Thierry Facon,Sara Bringhen,Michel Attal,Roberto Passera,Andrew Spencer,Massimo Offidani,Shantanu Kumar,Pellegrino Musto,Sagar Lonial,Maria Teresa Petrucci,Robert Z. Orlowski,Elena Zamagni,Gareth J. Morgan,Maletios A. Dimopoulos,Brian G.M. Durie,Kenneth C. Anderson,Pieter Sonneveld,Jesús F. San Miguel,Michele Cavo,S. Vincent Rajkumar,Philippe Moreau +29 more
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome
Hervé Avet-Loiseau,Michel Attal,Philippe Moreau,Catherine Charbonnel,Frédéric Garban,Cyrille Hulin,Serge Leyvraz,Mauricette Michallet,Ibrahim Yakoub-Agha,Laurent Garderet,Gerald Marit,Lucienne Michaux,Laurent Voillat,Marc Renaud,Bernard Grosbois,Gaelle Guillerm,Lotfi Benboubker,Mathieu Monconduit,Catherine Thieblemont,Philippe Casassus,Denis Caillot,Anne-Marie Stoppa,Jean-Jacques Sotto,Marc Wetterwald,Charles Dumontet,Jean-Gabriel Fuzibet,Isabelle Azais,Véronique Dorvaux,Marc Zandecki,Régis Bataille,Stephane Minvielle,Jean-Luc Harousseau,Thierry Facon,Claire Mathiot +33 more
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
John D. Shaughnessy,Fenghuang Zhan,Bart Burington,Yongsheng Huang,Simona Colla,Ichiro Hanamura,James P. Stewart,Bob Kordsmeier,Christopher Randolph,David R. Williams,Yan Xiao,Hongwei Xu,Joshua Epstein,Elias Anaissie,Somashekar G. Krishna,Michele Cottler-Fox,Klaus Hollmig,Abid Mohiuddin,Mauricio Pineda-Roman,Guido Tricot,Frits van Rhee,Jeffrey R. Sawyer,Yazan Alsayed,Ronald C. Walker,Maurizio Zangari,John Crowley,Bart Barlogie +26 more